OA17125A - Theurapeutic preparation and process for preparing said theurapeutic preparation - Google Patents
Theurapeutic preparation and process for preparing said theurapeutic preparation Download PDFInfo
- Publication number
- OA17125A OA17125A OA1201400409 OA17125A OA 17125 A OA17125 A OA 17125A OA 1201400409 OA1201400409 OA 1201400409 OA 17125 A OA17125 A OA 17125A
- Authority
- OA
- OAPI
- Prior art keywords
- préparation
- therapeutic
- substance
- ozone
- treatment
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 230000001225 therapeutic Effects 0.000 claims abstract description 37
- 239000003634 thrombocyte concentrate Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims description 38
- CBENFWSGALASAD-UHFFFAOYSA-N ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 32
- 241000282817 Bovidae Species 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000003102 growth factor Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000001143 conditioned Effects 0.000 claims 1
- 210000004080 Milk Anatomy 0.000 description 17
- 239000008267 milk Substances 0.000 description 17
- 235000013336 milk Nutrition 0.000 description 17
- 210000004369 Blood Anatomy 0.000 description 16
- 210000001772 Blood Platelets Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 14
- 230000003115 biocidal Effects 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000004396 Mastitis Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 6
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 6
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 6
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 6
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 6
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 6
- 229940079866 intestinal antibiotics Drugs 0.000 description 6
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 210000002264 Mammary Glands, Animal Anatomy 0.000 description 5
- 210000004293 Mammary Glands, Human Anatomy 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 210000001082 somatic cell Anatomy 0.000 description 5
- 210000002381 Plasma Anatomy 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000001804 emulsifying Effects 0.000 description 4
- 210000000481 Breast Anatomy 0.000 description 3
- 101700033006 EGF Proteins 0.000 description 3
- 102100010813 EGF Human genes 0.000 description 3
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 206010022114 Injury Diseases 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 229940053128 Nerve Growth Factor Drugs 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 230000035492 administration Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 235000020238 sunflower seed Nutrition 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102100019916 MSTN Human genes 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 108010008267 Nerve Growth Factors Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 101700038204 TGFA Proteins 0.000 description 2
- 102000036902 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000001172 regenerating Effects 0.000 description 2
- 230000003019 stabilising Effects 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;hydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940089206 Anhydrous Dextrose Drugs 0.000 description 1
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 1
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- YSFTYXKQUONNFY-NQXPEFQPSA-N FGF2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 description 1
- 102100006565 FLT1 Human genes 0.000 description 1
- 101710030892 FLT1 Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 229960001031 Glucose Drugs 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 210000002445 Nipples Anatomy 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 102100017669 SMAD2 Human genes 0.000 description 1
- 101700012842 SMAD2 Proteins 0.000 description 1
- 102100017680 SMAD4 Human genes 0.000 description 1
- 101700062085 SMAD4 Proteins 0.000 description 1
- 102100007381 SORT1 Human genes 0.000 description 1
- 108060009346 SORT1 Proteins 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 102000007374 Smad Proteins Human genes 0.000 description 1
- 108010007945 Smad Proteins Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 102100014223 TGFA Human genes 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 102000006747 Transforming growth factor alpha Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- OGIIWTRTOXDWEH-UHFFFAOYSA-N [O].[O-][O+]=O Chemical compound [O].[O-][O+]=O OGIIWTRTOXDWEH-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000000721 bacterilogical Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000031055 positive regulation of mitosis Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
A therapeutic preparation (1) comprising ozonised oil and a platelet concentrate (2), mixed according to a mixing ratio between the volumes of the platelet concentrate (2) and of the ozonised oil (3) substantially in the range between 2 and 4.
Description
The present invention relates to a therapeutic préparation and préparation process thereof, of the type as recîted in the preamble of the independent claims.
Preferably, the invention relates to a therapeutic préparation for the treatment of bovidae, such as a bovine (Bos taurus) or sheep (Ovis aries) and, more specifically, for the treatment of ailments of the mammary gland, preferably mastitis, of a bovine.
As known, mastitis consists of an inflammation of the udder caused by microorganisms which, penetrating inside the mammary gland through the nipple provoke a response of the immune system inside said mammary gland and thus cause physical, chemical and bacteriological changes in the milk.
For example, the onset of mastitis translates into a réduction in milk production which may cease entirely.
Above ail, gradually as the level of inflammation increases, the chemical composition of the milk increasingly resembles that of the blood on account of an alteration in the permeability of the membranes, which facilitâtes the filtration of haematic components from the blood circulation system to the udder, and a réduction in synthesis activity by the secretory tissue.
As a resuit, in some cases, the breeder, on account of the aforesaid alteration is forced to treat the animal with antibiotics for a period of time and discard the milk produced by the animal during such time.
A significant problem is lastly the fact that mastitis is diagnosed late and consequently, quantities of bad milk may be accidentally mixed with normal milk and be put on sale leading to problems of an enteric nature or other diseases in humans.
To résolve the aforesaid problème and therefore cure cases of mastitis, currently breeders use antibiotics.
The prior art described above has several significant drawbacks.
In fact the use of antibiotics or hormones causes residues of such substances in milk and thus créâtes heath problems in the consumer.
In particular, the presence of antibiotic residues in milk means that these can enter the human food chain increasing health risks to consumers, on account of the allergie, or in any case harmful effects which such substances may hâve.
In addition, the residues of said antibiotics transferred to humans from foods may contribute to the sélection of résistant bacteria in the individual who has consumed the contaminated food. In fact, over recent years the diffusion of antibiotic-resistant phenomena has become widespread, with possible risks to public health.
Another problem is therefore the fact that the milk produced when the bovine is treated with antibiotic must be discarded leading to économie losses for the breeder.
A further problem is the fact that the residues of antibiotics are also found in urine or other excrements which, dispersed in the environment, are sources of pollution.
Another drawback, of no less importance is the fact that antibiotics hâve a high cost and are not particulariy efficient.
In this situation the technical purpose of the présent invention is to develop a therapeutic préparation for the treatment of bovidae and a préparation process thereof able to substantially overcome the inconveniences mentioned above.
Within the sphere of said technical purpose one important aim of the invention is to obtain a therapeutic préparation for the treatment of bovidae which does not détermine the presence of residues in the milk harmful to humans.
Another important aim of the invention is consequently to make a therapeutic prépara tion for the treatment of bovidae which does not require discarding of the milk produced during the period of treatment.
A further aim of the invention is to devise a therapeutic préparation for the treatment of bovidae which is particulariy efficient and characterised by reduced environmental impact.
A no less important purpose is to obtain a préparation process of such therapeutic préparation which is easy and economical to perform.
The technical purpose and spécifie aims are achieved by a therapeutic préparation for the treatment of bovidae and a préparation process thereof as claimed in the appended claims. Preferred embodiments are described in the dépendent claims.
The characteristics and advantages of the invention are clearly évident from the following detailed description of a preferred embodiment thereof, with reference to the appended Fig. 1 showing a diagram of the préparation process of the therapeutic préparation for the treatment of bovidae according to the invention.
With reference to said drawings, reference numéral 1 globally dénotés the therapeutic préparation according to the invention.
It is suitable to be used for the treatment and cure of extemal and internai inflammatory states both of a person and of an animal and, preferably of a bovine, that is an animal belonging to the Bovidae family. In particular, the therapeutic préparation 1 is suitable to be used in a bovine for the treatment of ailments of the mammary gland, articular inflammations with or without bacterial or infectious complications and for the régénération of tissue to prevent tissue damage following injury, ageing. More in particular, the therapeutic préparation 1 is suitable to be used for the treatment of bovine (Bos taurus) mastitis.
The préparation 1 comprises, mainly, a substance of a proteic nature 2 and a substance in cluding ozone 3 preferably in solution in a fluid. Said fluid is preferably a liquid and more preferably an oil, so as to make an ozonised oil 3.
The substance of a proteic nature 2 is a substance composed of amino acids and thus consists of monomers, that is, amino acids, dimers or proteic polymers.
Preferably the substance of a proteic nature 2 is a combination of growth factors. The term growth factors, in use in the medical field, is taken to mean a substance of a proteic nature suitable to stimulate and regulate the prolifération of cells.
By way of a non-exhaustive example, the main function of growth factors is the externat control of the cellular cycle, through the abandonnant of cellular quiescence (phase GO) and the entrance of the cell in phase G1 (of growth). Growth factors further regulate the activation of mitosis, cellular survival, migration and cellular différentiation. As well as prolifération they always contemporarily promote différentiation and maturation.
Again by way of a non-exhaustive example, a list of some growth factors is given below:
- TGF-beta (transformïng growth factor),
- BMP (bone morphogenetic protein),
- neurotrophins (NGF, BDNF and NT3),
- FGF (fibroblast growth factor),
- Macrophage Colony-Stimulating Factor (M-CSF) or CSF-1,
- Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) or CSF-2,
- Granulocyte Colony-Stimulating factor (G-CSF) or CSF-3,
- nerve growth factor (NGF),
- neurotrophins,
- platelet derived growth factor (PDGF): tocated in the platelets and released by the α-granules thereof under various stimuli. It is also produced by macrophages. It also intervenes in the stabilisation of newly formed blood vessels, recruiting smooth muscle,
- insulin-like growth factors,
- erythropoietin (EPO),
- thrombopoietin (TPO),
- myostatin (GDF-8),
- growth différentiation factor-9 (GDF9),
- basic fibroblast growth factor (bFGF or FGF2),
- epidermal growth factor (EGF) also known as épithélial growth factor, induces mitosis and can be found in various biological liquide (saliva, urine, sweat). It bonds to the EGFR receptor usually known as ERB-B1,
- Hépatocyte growth factor (HGF),
- vascular endothélial growth factor (VEGF): it is implicated in processes such as inflammation, angiogenesis, ischémie cells. There are different types such as : VEGF A, B, C, D, E which bond to receptors such as VEGFR1, 2, 3 which hâve different locations and bind different VEGFs. The VEGF induce an increase in the permeability of the blood capillaries, resulting in the formation of oedema,
- TGF-α: Transforming growth factor-α implicated in almost all tumours. It bonds to the same receptor as the EGF and has the same effects,
- TGF-β: Transforming growth factor-β, produced by platelets, macrophages, lymphocytes. It is synthesised in two forms, one latent and one active. The active form bonds first to the receptor2 forming a primary stable complex, which bonds to the receptorl, forming the secondary stable complex, which entails the phosphorylation of the SMAD transcription factors among which: SMAD2 and 3, which then bond to the SMAD4 transcription factor. A heterodimer results which is able to enter inside the nucléus and favour or inhibit gene activation. The TGF-β détermines an increase in the concentration of factors inhibiting the CDK, causing blocking of the cellular cycle. It also intervenes in the stabilisation of newly formed blood vessels, recruiting matricellular proteins.
Preferably the combination of growth factors is a platelet concentrate.
It is substantially composed of a haematic component, that is blood extract, the platelet concentration of which is preferably at least 10e platelets /m! and appropriately, substantially equal to 109 platelets /ml.
It îs preferably of the allologous type, in other words obtained from a blood sample deriving from the same species, in particular bovidae or from the same breed including an animal which the préparation 1 is used on.
In another preferred solution the combination of growth factors is of the type contained in the Stem Cells Conditioned Medium.
The substance including ozone 3 is produced using any process, it may be pure ozone or ozone mixed with oxygen or not. Preferably it is ozone in solution in a fluid, or altematively in a solid, and more preferably ozonised oil 3 which is substantially ozone emulsified with oil or similar substances and preferably emulsified with sunflower seed oil and, if required by spécifie applications, other additional components. It is composed of a gaseous liquid solution in which the ozone is preferably saturated.
The mixing ratio between the volumes of the substance of a proteic nature 2 and the substance including ozone 3, in the case în which the substance of a proteic nature 2 is a platelet concentrate and the substance including ozone 3 is ozonised oil is preferably substantially in the range between 2 and 4. Preferably, said mixing ratio is substantially in the range between 2.5 and 3.5 and, more preferably, close to 3, that is three parts of substance of a proteic nature 2 and one part of ozone.
The invention further relates to a process for preparing the therapeutic préparation described above for the treatment of bovidae.
Such préparation process 10 comprises a step 11 of taking a sample in which a sample of blood lia is taken from the bovine; a séparation step 12 in which the platelet concentrate 2 is extracted from the blood sample; an emulsifying step 13 in which the ozonised oil 3 is obtained by blowing ozone into the oil; a mixing step 14 in which the substance including ozone 3 and the platelet concentrate 2 are mixed; and a cooling step 15 in which the therapeutic préparation 1 is deep-frozen.
In the step of taking a sample, the operator selects one or two bovidae and extracts a blood sample lia. In particular, the blood sample lia is extracted from healthy bovines, that is, characterîsed by a practically perfect state of health and thus free of the disease which the therapeutic préparation 1 is to address.
In particular, during the step of taking a sample 11, the sample 1 la is extracted for example with a syringe 11b through an outer jugular venipuncture or from the subcutaneous mammary vein, using a 16 gauge needle, substantially corresponding to 16.83 mm, and then collected in blood bags.
The blood sample 1 la is then collected in bags made from PVC and containing an anticoagulant and preservative additive such as, for example, CPDA-1. More in particular, the blood sample lia is collected in blood bags which, for every 100 ml of blood substantially contain 0.327 g of monohydrate citric acid, 2.63 g of dihydrate sodium citrate, 0.251 g of dihydrate monosodium phosphate, 2.90 g of anhydrous dextrose and 0.0275 g of adenine.
Once the sample has been taken, step 11 is completed by placing the bags inside spécial refrigerators so as to keep them at a température substantially equal to 4°C.
Within twenty-four hours of taking the sample the process provides for a séparation step 12 in which the substance of a proteîc nature 2 is extracted from the blood sample I la of the bovine. In detail, the blood is processed în such a manner as to obtain the substance of a proteîc nature 2 characterised by a content of platelets substantially equal to 109 platelets /ml.
In particular, in the step 12 the blood sample 1 la is subjected to two centrifuging cycles, one at a low speed and one at a high speed, so as to avail of the different densities of the various éléments présent in the blood sample I la.
More in particular, the step 12 may involve a first centrifuging cycle at low revs (100 revs /min for 30 minutes) so as to separate the plasma rich in platelets 12b from the red blood cells or other discards 12c, a second centrifuging cycle at high revs (1500 revs /min for 10 minutes) in which the substance of a proteîc nature 2 and the discard material composed of Platelet Poor Plasma (ppp) 12c is extracted from the plasma rich in platelets.
Lastly, should the substance of a proteîc nature 2 thus obtained not hâve the desired platelet concentration, the séparation step 12 provides for its dilution with Platelet Poor Plasma (ppp) 12c so as to obtain the desired concentration (109 platelets /ml).
In the emulsifying step 13 the ozonised oîl îs prepared by blowing a mixture of oxygenozone 13a into oil 13b and preferably, into sunflower seed oil, preferably cold-pressed sunflower seed oïl.
In detail, În such step 13 a stérile récipient 13c is partially filled with the oïl 13b and then a mixture of oxygen-ozone at a concentration of 30 pg/ml is blown into it for 15 minutes so as to cause the emulsifying of the oil, and then the ozone 13b and the oil 13a are appropriately mixed to obtain the substance including ozone 3.
Once the emulsifying step 13 has been completed there is a mixing step 14 in which the substance including ozone 3 and the platelet concentrate 2 are mixed together.
In detail, in such step 14 the mixing ratio between the volumes of the content of the substance of a proteic nature 2 and of the content of the substance including ozone 3, preferably of the substance including ozone 3, is substantialiy in the range between 1 and 5. Preferably, said mixing ratio between the volumes of the concentrate 2 and of the ozonised oil 3 is substantiaily in the range between 2 and 4, more preferably in the range between 2.5 and 3.5 and, even more preferably, substantiaily equal to 3.
The cooling step 15 follows at this point in which the therapeutic préparation 1 is deepfrozen and in particular is brought to a température substantiaily equal to -80°C for at Ieast 12 hours or is treated with liquid nitrogen for a shorter period of time.
Such step is obtained for example by the mere collection of a sample using a syringe of a dose of platelet concentrate and a subséquent collection of a sample of ozone in the fluid. Given its inferior spécifie weight the ozone rises to the surface and remains partially in solution in the platelet concentrate which it has passed through.
In the cooling step 15, at the end of said 12 hours the therapeutic préparation 1 is thawed at a température in the range between +20°C and 25°C for 12 hours and then deep-frozen once again at -80°C for 12 hours. Such step has the function of exploding the platelet cells which thus makes the necessary factors emerge. Altemativeiy, said step may be replaced or combined with the addition of calcium ions (Ca+ or Ca**) which cause the said necessary factors to emerge from the platelet cells.
After completing the cooling step 15, the process involves a final preserving step 16, in which the therapeutic préparation is preserved until the moment of use at approximately 20°C.
The invention achieves some important advantages.
A first fundamental advantage is given by the innovative combination of a substance induding ozone 3 and a substance of a proteic nature 2.
It achieves important advantages for the treatment of animais or people and as an antibiotic, anti-inflammatory product, antiseptie, tissue restructuring and regenerating product induding the function of preventing tissue damage and/or the functional recovery of organ and/or tissues and/or following injury and/or disease and/or ageing.
In particular it is significantly advantageous as an antibiotic.
In detail it makes it possible to obtain an extremely efficient product for treating mastitis or other inflammations of the mammary gland.
Such aspect is also ensured by the cooting step 15 which, by bringing the préparation to -80°C favours the reiease of the platelet factors characteristic of the préparation 1.
Moreover, the aforesaid combination makes the préparation 1 extraordinarily efficient in the treatment of a bovine or other animal or even humans as an antibiotic, antiinflammatory product, antiseptie, tissue restructuring product for the treatment of externat and internai inflammations, articular inflammation, bacteria and/or infectîous complications, with a great tissue regenerating capacity and préventive function of tissue damage following injury or ageing.
One important advantage lies in the fact that, thanks to the particular composition of the therapeutic préparation 1, the milk produced during treatment with the therapeutic préparation 1 is free of residues of antibiotic and can thus be used by the consumer without any risk to health.
Another advantage is therefore the fact that, the use of the therapeutic préparation 1 does not require the milk producing during treatment to be discarded.
Moreover, such advantage is increased by the fact that the therapeutic préparation 1, thanks to the combination of ozonised oit and platelet concentrate, does not involve a réduction in milk production.
A further advantage is the fact that, the concentrate 2 being of the allologous type, the préparation 1 is much better tolerated and practically free of side effects or adverse reactions.
Another advantage of no Iess importance is the reduced cost both of the therapeutic préparation 1 and of the process 10 compared to those currently known.
A further important advantage is the extreme versatility of use of the therapeutic préparation 1 which, in fact, may be injected by means of a syringe, applied extemally in the form of a cream (for example to the knee or a muscle) or internaily (for example inside the utérus or mouth), or enclosed in a pill or the like to be swallowed by the bovine.
It is therefore easily utilisable for example in intramuscular, mammary intracanalicular, ïntrauterine, transdermal, subeutaneous, intra-articular administrations but also by an enterai route, including oral, buccal or sublingual, rectal, therein including Ïntrauterine and mammary intra-canalicular route, by a parentéral route among which intravenous, intramuscular, subeutaneous, inhalatory, intra-arterial, intrathecal, intraperitoneal, intra-articular and intradermal, locally or topically, among which cutaneous, transdermal, nasal, ophthalmic or auricular routes.
An experimental study of bovidae has verified the number of somatic cells présent in a plurality of samples including milk from said bovidae taken before and after administration of the préparation 1 alone.
Said bovidae were treated with a daily dose, for four days in a row, of 6 ml of platelet concentrate 2 together with 2 ml of ozonised oil 3.
As known, the number of somatic cells présent in milk is directly proportionate to the degree of infection of the related udder.
The resuit was as follows: on the day of administration the mean number of somatic cells présent in the milk samples was approximately 9,658,182; seven days later they had de creased by 84% to a mean total of approxlmately 1,548,364 in the samples; a fortnlght later the somatic cells had decreased by 97% to a mean total of approxlmately 276,455 in the samples; thirty days later the somatic cells had decreased by 99% to a mean total of approximately 125,364 in the samples.
Another advantage is that the process 1 and the préparation 1 are practically free of pollutant agents.
Claims (12)
1. A therapeutic préparation (1) characterised in that it comprises a substance including ozone (3) and a substance of a proteic nature (2).
2. A therapeutic préparation (1) as claimed in claim 1, wherein said substance of a proteic nature (2) is a combination of growth factors.
3. A therapeutic préparation (1) as claimed in claim 2, wherein said substance of a proteic nature (2) is a platelet concentrate.
4. A therapeutic préparation (1) as claimed in claim 2, wherein said substance of a proteic nature (2) is a medium conditioned by stem cells.
5. A therapeutic préparation (1) as claimed în one or more of the preceding claims, wherein said substance including ozone (3) îs ozone in solution in a fluid.
6. A therapeutic préparation (1) according to the preceding claim, wherein said ozone is in solution in oil.
7. A therapeutic préparation (1) as claimed in one or more of the preceding claims, wherein said substance including ozone (3) is ozonised oil.
8. A therapeutic préparation (1) as claimed in claims 7 and 3, wherein the ratio of the content of said platelet concentrate (2) to the content of said fluid including ozone (3) is in the range between 2 and 4.
9. A therapeutic préparation (1) according to the preceding claim, for the treatment of bovine mastitîs.
10. A process for preparing a therapeutic préparation (1) for treatment of bovidae, characterised in that it comprises a mixing step in which a substance including ozone (3) and a substance of a proteic nature (2) are mixed.
11. A préparation process according to one or more of the previous claims, comprising a cooling step (15) in which said therapeutic préparation (1) is brought to a température substantially equal to -80°C.
12. A préparation process according to one or more of the previous claims, com prising a cooling step (15) in which said therapeutic préparation (1) is frozen with liquid nitrogen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2012A000338 | 2012-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17125A true OA17125A (en) | 2016-03-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10980837B2 (en) | Lyophilized platelet lysates | |
US11786556B2 (en) | Method for preparing a growth factors containing platelet releasate | |
ES2639561T3 (en) | Procedure for preparing a growth factor concentrate derived from human platelets | |
CN108486047B (en) | Medical dressing of stem cell extract and preparation method thereof | |
CN109044948A (en) | A kind of autologous collagen albumen water laser accunputure and preparation method thereof | |
CN105056286B (en) | Liquid adhesive bandage and preparation method thereof | |
CN106754639A (en) | A kind of mescenchymal stem cell factor large-scale producing method | |
US20090081181A1 (en) | Isolation of growth and differentiating factors from colostrum | |
WO2017043953A2 (en) | Process for obtaining a sprinkling compound of microvascular endothelial skin cells and mesenchymal stem cells and method of application for tissue regeneration | |
US20150071893A1 (en) | Therapeutic preparation and process for preparing siad therapeutic preparation | |
JP2020500933A (en) | Method for the preparation and long-term storage of growth factors and cytokines obtained from platelet-rich plasma | |
CN104586778A (en) | External recombinant bovine basic fibroblast growth factor lyophilized preparation | |
RU2543344C2 (en) | Method of treating trophic ulcers | |
OA17125A (en) | Theurapeutic preparation and process for preparing said theurapeutic preparation | |
WO2017082441A1 (en) | Veterinary medicinal composition for treatment of wound of animal comprising activated platelet-rich plasma as active ingredient | |
KR20150061806A (en) | Veterinary composition for wound healing of animal containing activated platelet rich plasma | |
CN114303454B (en) | Virus inactivation method of biological product DBT | |
WO2024117059A1 (en) | Method for producing gel-like wound healing agent, gel-like wound healing agent, and autologous platelet-rich plasma gel preparation kit for wound healing | |
RU2795884C2 (en) | Method for obtaining platelet releasate containing growth factors | |
Pavlenko et al. | Using PRGF-Endoret Technique for the Regeneration of Soft Tissues Defects Applied in Regenerative Medicine | |
CA2580372C (en) | Isolation of growth and differentiating factors from colostrum | |
WO2022269035A1 (en) | Preparation method and container for a topical wound healing gel | |
Tykhvynska et al. | Mesenchymal Stromal Cells Within Fibrin Gel Stimulate Healing of Full-Thickness Wounds in Mice | |
Poulsen et al. | Treatment of Haemophilia with Dried Human Fibrinogen |